Recital 8, Regulation (EU) 2024/1892

In forcesince 10 Jul 2024

For the active substances thiencarbazone and valifenalate, as the risk assessment has not yet been finalised by the respective rapporteur Member States and in light of the time required to complete the remaining steps in each renewal procedure, the duration of the extension of the approval periods should be set at 29 months.